Sara Castro-Alonso

Oviedo, AS 33011, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Treatment Persistence and Factors Associated with Bimekizumab Discontinuation in Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Multicenter Study.

Treatment Persistence and Factors Associated with Bimekizumab Discontinuation in Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Multicenter Study.

Journal: Biomedicines

Published: July 03, 2026

Achlorophyllic algae and chronic bursitis: An exceptional association.

Achlorophyllic algae and chronic bursitis: An exceptional association.

Journal: Reumatologia clinica

Published: May 27, 2025

Decreased GPR55 expression links B-cell activation and vascular remodelling in atherosclerosis in patients with early rheumatoid arthritis.

Decreased GPR55 expression links B-cell activation and vascular remodelling in atherosclerosis in patients with early rheumatoid arthritis.

Journal: RMD open

Published: April 21, 2025

Higher frequencies of age-associated B-cells in early arthritis are linked to atherosclerosis and immune circuits-a potential role as a biomarker for risk stratification.

Higher frequencies of age-associated B-cells in early arthritis are linked to atherosclerosis and immune circuits-a potential role as a biomarker for risk stratification.

Journal: Rheumatology (Oxford, England)

Published: January 14, 2025

Do the Activity Indices Used in Axial Spondyloarthritis Capture the Relationships Between Obesity, Smoking and Disease Activity in the Same Way?

Do the Activity Indices Used in Axial Spondyloarthritis Capture the Relationships Between Obesity, Smoking and Disease Activity in the Same Way?

Journal: Journal of clinical medicine

Published: October 06, 2024

C-reactive protein thresholds for discriminating active disease in axial spondyloarthritis: should we lower them?

C-reactive protein thresholds for discriminating active disease in axial spondyloarthritis: should we lower them?

Journal: Clinical and experimental rheumatology

Published: August 03, 2024

Do patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with?

Do patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with?

Journal: Journal of Crohn's & colitis

Published: April 17, 2024

Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.

Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.

Journal: Frontiers in immunology

Published: April 10, 2023

Acroosteolysis and facial dysmorphia: a new case of Hajdu-Cheney syndrome.

Acroosteolysis and facial dysmorphia: a new case of Hajdu-Cheney syndrome.

Journal: Reumatologia clinica

Published: March 06, 2023

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes.

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes.

Journal: Journal of clinical medicine

Published: November 20, 2022

Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages.

Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages.

Journal: Rheumatology (Oxford, England)

Published: November 10, 2022

Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

Journal: Frontiers in medicine

Published: November 18, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026